- Home
- TSI vs SERA Comparison
TSI vs SERA Comparison
Compare TSI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | SERA |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 75.2M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TSI | SERA |
|---|---|---|
| Price | $4.53 | $2.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 105.9K | 60.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $4.43 | $1.37 |
| 52 Week High | $5.06 | $4.09 |
Technical Indicators
Market Signals| Indicator | TSI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 61.27 |
| Support Level | $4.43 | $1.67 |
| Resistance Level | $4.63 | $2.41 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 37.50 | 77.79 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.